Dihydroartemisinin inhibits tumor growth of human osteosarcoma cells by suppressing Wnt/β-catenin signaling

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1723-1730

  Liu, Yueliang ^a   Wang, Wenjuan ^a   Xu, Jing ^a   Li, Li ^a   Dong, Qian ^a   Shi, Qiong ^a   Zuo, Guowei ^a   Zhou, Lan ^a   Weng, Yaguang ^a   Tang, Min ^a   He, Tongchuan ^b   Luo, Jinyong ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Dihydroartemisinin; Osteosarcoma; Tumor growth; Wnt catenin signaling

Indexed keywords

BETA CATENIN; CYCLOOXYGENASE 2; DIHYDROARTEMISININ; GELATINASE B; GLYCOGEN SYNTHASE KINASE 3BETA; VASCULOTROPIN; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BONE STRUCTURE; CANCER INHIBITION; CANCER SIZE; CATALYSIS; CELL INVASION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTIMALARIALS; APOPTOSIS; ARTEMISININS; BETA CATENIN; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLOOXYGENASE 2; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; OSTEOSARCOMA; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84882565009     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2658     Document Type: Article

References (12)

1. Tang N, Song WX, Luo J, Haydon RC and He TC: Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 466: 2114-2130, 2008.
2. Whelan JS: Osteosarcoma. Eur J Cancer 33: 1618-1619, 1997.
3. Kager L, Zoubek A, Kastner U, et al: Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 24: 1535-1541, 2006.
4. Kager L, Zoubek A, Pötschger U, et al: Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21: 2011-2018, 2003.
5. Geller DS and Gorlick R: Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 8: 705-718, 2010.
6. Ferrari S and Palmerini E: Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 19: 341-346, 2007.
7. Tang N, Song WX, Luo J, Haydon RC and He TC: Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 466: 2114-2130, 2008.
8. Whelan JS: Osteosarcoma. Eur J Cancer 33: 1618-1619, 1997.
9. Kager L, Zoubek A, Kastner U, et al: Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 24: 1535-1541, 2006.
10. Kager L, Zoubek A, Pötschger U, et al: Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21: 2011-2018, 2003.
11. Geller DS and Gorlick R: Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 8: 705-718, 2010.
12. Ferrari S and Palmerini E: Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 19: 341-346, 2007